Profiel
Premal Patel worked as Head-Early Clinical Development at Pfizer Inc. from 2015 to 2017.
He then worked as SVP & Head-Early Clinical Drug Development at Juno Therapeutics, Inc. from 2017 to 2018.
From 2018 to 2020, he served as Chief Medical Officer at Lyell Immunopharma, Inc. In 2021, he worked as Chief Medical Officer at eFFECTOR Therapeutics, Inc. Patel holds a doctorate degree from the University of Washington and an undergraduate degree from Rutgers State University of New Jersey.
Eerdere bekende functies van Premal Patel
| Bedrijven | Functie | Einde |
|---|---|---|
| EFFECTOR THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-04-2022 |
| LYELL IMMUNOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 01-04-2020 |
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01-04-2018 |
| PFIZER, INC. | Corporate Officer/Principal | 01-08-2017 |
Opleiding van Premal Patel
| University of Washington | Doctorate Degree |
| Rutgers State University of New Jersey | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| EFFECTOR THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
